Search

Your search keyword '"Lee, Craig R."' showing total 10 results
Start Over Author "Lee, Craig R." Journal pharmacogenetics and genomics
10 results on '"Lee, Craig R."'

1. The Pharmacogenomics Global Research Network Implementation Working Group: global collaboration to advance pharmacogenetic implementation

Author

Cavallari, Larisa H., Hicks, J. Kevin, Patel, Jai N., Elchynski, Amanda L., Smith, D. Max, Bargal, Salma A., Fleck, Ashley, Aquilante, Christina L., Killam, Shayna R., Lemke, Lauren, Ochi, Taichi, Ramsey, Laura B., Haidar, Cyrine E., Ho, Teresa, El Rouby, Nihal, Monte, Andrew A., Allen, Josiah D., Beitelshees, Amber L., Bishop, Jeffrey R., Bousman, Chad, Campbell, Ronald, Cicali, Emily J., Cook, Kelsey J., Duong, Benjamin, Tsermpini, Evangelia Eirini, Girdwood, Sonya Tang, Gregornik, David B., Grimsrud, Kristin N., Lamb, Nathan, Lee, James C., Lopez, Rocio Ortiz, Mazhindu, Tinashe Adrian, Morris, Sarah A., Nagy, Mohamed, Nguyen, Jenny, Pasternak, Amy L., Petry, Natasha, van Schaik, Ron H.N., Schultz, April, Skaar, Todd C., Al Alshaykh, Hana, Stevenson, James M., Stone, Rachael M., Tran, Nam K., Tuteja, Sony, Woodahl, Erica L., Yuan, Li-Chi, and Lee, Craig R.

Published
2025
Full Text
View/download PDF

2. The Pharmacogenomics Global Research Network Implementation Working Group: global collaboration to advance pharmacogenetic implementation

Author

Cavallari, Larisa H., Hicks, J. Kevin, Patel, Jai N., Elchynski, Amanda L., Smith, D. Max, Bargal, Salma A., Fleck, Ashley, Aquilante, Christina L., Killam, Shayna R., Lemke, Lauren, Ochi, Taichi, Ramsey, Laura B., Haidar, Cyrine E., Ho, Teresa, El Rouby, Nihal, Monte, Andrew A., Allen, Josiah D., Beitelshees, Amber L., Bishop, Jeffrey R., Bousman, Chad, Campbell, Ronald, Cicali, Emily J., Cook, Kelsey J., Duong, Benjamin, Tsermpini, Evangelia Eirini, Girdwood, Sonya Tang, Gregornik, David B., Grimsrud, Kristin N., Lamb, Nathan, Lee, James C., Lopez, Rocio Ortiz, Mazhindu, Tinashe Adrian, Morris, Sarah A., Nagy, Mohamed, Nguyen, Jenny, Pasternak, Amy L., Petry, Natasha, van Schaik, Ron H.N., Schultz, April, Skaar, Todd C., Al Alshaykh, Hana, Stevenson, James M., Stone, Rachael M., Tran, Nam K., Tuteja, Sony, Woodahl, Erica L., Yuan, Li-Chi, and Lee, Craig R.

Published
2024
Full Text
View/download PDF

7. ??1-Adrenergic receptor polymorphisms and left ventricular remodeling changes in response to ??-blocker therapy

Author

Terra, Steven G., primary, Hamilton, Karen K., additional, Pauly, Daniel F., additional, Lee, Craig R., additional, Herbert Patterson, J., additional, Adams, Kirkwood F., additional, Schofield, Richard S., additional, Belgado, Bernadette S., additional, Hill, James A., additional, Aranda, Juan M., additional, Yarandi, Hossein N., additional, and Johnson, Julie A., additional

Published
2005
Full Text
View/download PDF

8. CYP2J2and CYP2C8polymorphisms and coronary heart disease risk the Atherosclerosis Risk in Communities (ARIC) study

Author

Lee, Craig R., North, Kari E., Bray, Molly S., Couper, David J., Heiss, Gerardo, and Zeldin, Darryl C.

Abstract

The cytochromes P450 epoxygenases CYP2J2 and CYP2C8 synthesize epoxyeicosatrienoic acids, which regulate endothelial function. We sought to determine if genetic variation in CYP2J2and CYP2C8was associated with coronary heart disease risk.

Published
2007
Full Text
View/download PDF

9. NOS3polymorphisms, cigarette smoking, and cardiovascular disease risk The Atherosclerosis Risk in Communities study

Author

Lee, Craig R., North, Kari E., Bray, Molly S., Avery, Christy L., Mosher, Mary Jane, Couper, David J., Coresh, Josef, Folsom, Aaron R., Boerwinkle, Eric, Heiss, Gerardo, and Zeldin, Darryl C.

Abstract

Endothelial nitric oxide synthase (NOS3) activity and cigarette smoking significantly influence endothelial function. We sought to determine whether cigarette smoking modified the association between NOS3polymorphisms and risk of coronary heart disease or stroke.

Published
2006
Full Text
View/download PDF

10. Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy.

Author

Terra SG, Hamilton KK, Pauly DF, Lee CR, Patterson JH, Adams KF, Schofield RS, Belgado BS, Hill JA, Aranda JM, Yarandi HN, and Johnson JA

Subjects
Codon, Echocardiography, Female, Genotype, Heart Ventricles drug effects, Heart Ventricles pathology, Heterozygote, Homozygote, Humans, Male, Maximum Tolerated Dose, Middle Aged, Pharmacogenetics, Receptors, Adrenergic metabolism, Regression Analysis, Systole, Time Factors, Ventricular Remodeling, Adrenergic beta-Antagonists pharmacology, Heart Failure drug therapy, Heart Failure genetics, Polymorphism, Genetic, Receptors, Adrenergic, beta-1 genetics
Abstract

Objective: Large variability exists in the improvement in left ventricular (LV) function from beta-blocker treatment. We hypothesized that polymorphisms at codon 389 (Arg389Gly) and 49 (Ser49Gly) in the beta1-adrenergic receptor (AR) gene were associated with LV reverse remodeling changes in response to beta-blocker therapy among heart failure patients., Methods: We prospectively enrolled 61 beta-blocker naive patients with systolic heart failure. Patients underwent baseline echocardiography followed by metoprolol CR/XL. The dose was doubled on a biweekly basis up to 200 mg/day or attainment of maximum tolerated dose. Echocardiography was repeated after the patient received the target or highest tolerated dose for 3 months., Results: Among patients with the Arg389Arg genotype, ejection fraction (EF) increased from 23+/-5 to 29+/-10 (P=0.008). Gly389 carriers did not demonstrate any significant change in EF (22+/-9 to 23+/-11; P=0.45). There was a significant between-group difference in EF by genotype (P=0.04). The Arg389Arg genotype was also associated with significantly greater reductions in LV end-diastolic and end-systolic diameters compared to Gly389 carriers. Patients with the Gly49 variant also had a significantly greater reduction in LV end-diastolic diameter compared to Ser49 homozygotes. Multiple regression analysis modeling revealed that the codon 389 polymorphism was a significant predictor of an improvement in EF and both codon 49 and 389 polymorphisms were significant predictors of final LV end-diastolic diameter., Conclusions: Heart failure patients with the Arg389Arg genotype and Gly49 carriers had greater improvements in LV remodeling from beta-blocker treatment.

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results